Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “STAT3”

48 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 48 results

Early research (Phase 1)Study completedNCT00955812
What this trial is testing

STAT3 Inhibitor for Solid Tumors

Who this might be right for
Advanced CancerSolid Tumor
M.D. Anderson Cancer Center 24
Not applicableUnknownNCT02967419
What this trial is testing

The Study of the Relationship Between TWEAK/Fn14, JAK/STAT3 and IDO in the Immune Microenvironment of Endometrium in Repeated Implantation Failure

Who this might be right for
Repeated Implantation Failure
ZhangTao 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07831187
What this trial is testing

Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence

Who this might be right for
Glioblastoma
First Affiliated Hospital of Wenzhou Medical University 96
Testing effectiveness (Phase 2)WithdrawnNCT05668949
What this trial is testing

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

Who this might be right for
Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT06098651
What this trial is testing

DCR-STAT3 in Adults With Solid Tumors

Who this might be right for
Solid Tumor, AdultRefractory Tumor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 26
Testing effectiveness (Phase 2)Study completedNCT01563302
What this trial is testing

Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers

Who this might be right for
Advanced CancersDLBCLLymphoma
Ionis Pharmaceuticals, Inc. 64
Early research (Phase 1)Study completedNCT01904123
What this trial is testing

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain

Who this might be right for
Metastatic Malignant Neoplasm in the BrainMetastatic MelanomaRecurrent Brain Neoplasm+2 more
M.D. Anderson Cancer Center 8
Early research (Phase 1)Study completedNCT04702503
What this trial is testing

Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)

Who this might be right for
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Moleculin Biotech, Inc. 5
Not applicableStudy completedNCT07055256
What this trial is testing

Elucidating the Role of STAT3 in Epithelial-microbiome Interaction During Periodontitis and Peri-implantitis

Who this might be right for
PeriodontitisPeri-implantitis
University of Chile 43
Not applicableEnded earlyNCT01663571
What this trial is testing

STAT3 in T Cells: At The Crossroads of Inflammation and Cancer

Who this might be right for
Cutaneous T Cell Lymphoma
NYU Langone Health 35
Early research (Phase 1)Study completedNCT03195699
What this trial is testing

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Who this might be right for
Breast CancerHead and Neck Squamous Cell CarcinomaNon Small Cell Lung Cancer+5 more
Tvardi Therapeutics, Incorporated 64
Testing effectiveness (Phase 2)Study completedNCT01066663
What this trial is testing

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia
Dana-Farber Cancer Institute 20
Testing effectiveness (Phase 2)Looking for participantsNCT06894225
What this trial is testing

Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature

Who this might be right for
Recurrent Glioblastoma
National Neuroscience Institute 12
Early research (Phase 1)Study completedNCT01423903
What this trial is testing

Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer

Who this might be right for
Advanced Cancer
Otsuka Pharmaceutical Development & Commercialization, Inc. 45
Early research (Phase 1)Looking for participantsNCT07262983
What this trial is testing

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Who this might be right for
Hyper IgE Syndrome From STAT3 MutationJob s SyndromeHIES+2 more
National Institute of Allergy and Infectious Diseases (NIAID) 20
Testing effectiveness (Phase 2)Study completedNCT03647839
What this trial is testing

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Australasian Gastro-Intestinal Trials Group 90
Not applicableLooking for participantsNCT00001467
What this trial is testing

Genetic Analysis of Immune Disorders

Who this might be right for
DOK 8STAT1GATA2+2 more
National Institute of Allergy and Infectious Diseases (NIAID) 5,000
Early research (Phase 1)Study completedNCT02549651
What this trial is testing

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Who this might be right for
Diffuse Large B-Cell Lymphoma
MedImmune LLC 32
Very early researchStudy completedNCT01568996
What this trial is testing

Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions

Who this might be right for
Atypical NeviMelanoma
John Kirkwood 17
Early research (Phase 1)Study completedNCT05440942
What this trial is testing

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Peter Hosein, MD 28
Next Page